Related Experiment Video

Updated: Jul 18, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.5K

Oncolytic Virus Engineering and Utilizations: Cancer Immunotherapy Perspective

Palaniyandi Muthukutty1, So Young Yoo1

  • 1BIO-IT Foundry Technology Institute, Pusan National University, Busan 46241, Republic of Korea.

Viruses
|August 26, 2023
PubMed

Insights

Oncolytic viruses, both natural and modified, are advancing cancer immunotherapy. This review explores virus engineering strategies and clinical trial progress for improved virotherapeutics.

Area of Science:

  • Oncology
  • Virology
  • Immunotherapy

Background:

  • Oncolytic viruses have significantly advanced cancer immunotherapy over the last two decades.
  • Both naturally occurring and genetically engineered viruses demonstrate potential in treating diverse cancers.
  • Four oncolytic viruses have received global regulatory approval, with ongoing development for enhanced anti-tumor efficacy.

Purpose of the Study:

  • To review virus engineering strategies for oncolytic virotherapeutics.
  • To discuss the progress of clinical trials involving oncolytic viruses.
  • To provide insights into future technologies for oncolytic virus development.

Main Methods:

  • Review of scientific literature on oncolytic virus engineering.
  • Analysis of clinical trial data and outcomes.
  • Discussion of modification strategies and their impact on anti-tumor responses.

Main Results:

  • Oncolytic viruses show promising results in treating various cancers.
  • Advancements in virus engineering are crucial for overcoming limitations and improving treatment outcomes.
  • Ongoing clinical trials are evaluating the efficacy and safety of novel oncolytic agents.

Conclusions:

  • Faster translation of research into commercialization is essential for cancer immunotherapy.
  • A deeper understanding of virus modification strategies will drive future oncolytic virus technologies.
  • Continued research and development in oncolytic virotherapeutics hold significant promise for cancer treatment.
Keywords:
cancerclinical trialsimmunotherapyoncolytic virusvirotherapy

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.1K
Ex Vivo Infection of Live Tissue with Oncolytic Viruses12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

12.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
555
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
400
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.1K